Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial
NCT06510699
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This project aims to address invasive fungal infections in patients, by precision dosing of voriconazole based on CYP2C19 genotype testing with Bayesian dose-forecasting dosing software to develop patient-centric and maximally effective dosing regimens.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Fungal Infection
- Haematological Malignancy
- Blood Cancer
- Infectious Disease
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 2 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- The University of Queensland
- Last updated on ClinicalTrials.gov
- April 16, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Washington · 1
- Fred Hutchinson Cancer Centre · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.